Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation - PubMed (original) (raw)
Clinical Trial
Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation
K Rickels et al. Arch Gen Psychiatry. 1990 Oct.
Erratum in
- Arch Gen Psychiatry 1991 Jan;48(1):51
Abstract
We compared the effect of abrupt discontinuation of therapeutic doses of short half-life and long half-life benzodiazepines in 57 benzodiazepine-dependent patients (daily use, greater than 1 year). Despite the use of a mean daily dose of 14.1 mg of diazepam equivalents, there were notable residual symptoms of anxiety and depression present at intake (Hamilton Rating Scale for Anxiety score, 17.0; Hamilton Rating Scale for Depression score, 14.0). Benzodiazepine intake was stabilized for 3 weeks before double-blind assignment to placebo (n = 47), or continued benzodiazepine use (n = 10). Clinical assessments were performed daily, including benzodiazepine plasma levels. Depending on the outcome criteria used, anywhere from 58% to 100% of patients were judged to have experienced a withdrawal reaction, with a peak severity at 2 days for short half-life and 4 to 7 days for long half-life benzodiazepines. Relapse onto benzodiazepines occurred in 27% of patients who were receiving long half-life benzodiazepines and in 57% of patients who were receiving short half-life benzodiazepines. Baseline predictors of relapse were nonpanic diagnoses, a higher benzodiazepine dose, and a higher Eysenck neuroticism score. A short half-life and higher daily doses were associated with greater withdrawal severity, as were personality traits, such as dependency and neuroticism, less education and higher baseline levels of anxious and depressive symptoms. Patients who were able to remain free of benzodiazepines for at least 5 weeks obtained lower levels of anxiety than before benzodiazepine discontinuation. These results provide a detailed picture of the symptoms, time course, and multidimensional determinants of the benzodiazepine withdrawal syndrome.
Similar articles
- Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper.
Schweizer E, Rickels K, Case WG, Greenblatt DJ. Schweizer E, et al. Arch Gen Psychiatry. 1990 Oct;47(10):908-15. doi: 10.1001/archpsyc.1990.01810220024003. Arch Gen Psychiatry. 1990. PMID: 2222130 Clinical Trial. - Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment.
Fontaine R, Chouinard G, Annable L. Fontaine R, et al. Am J Psychiatry. 1984 Jul;141(7):848-52. doi: 10.1176/ajp.141.7.848. Am J Psychiatry. 1984. PMID: 6145363 Clinical Trial. - Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy.
Rickels K, DeMartinis N, García-España F, Greenblatt DJ, Mandos LA, Rynn M. Rickels K, et al. Am J Psychiatry. 2000 Dec;157(12):1973-9. doi: 10.1176/appi.ajp.157.12.1973. Am J Psychiatry. 2000. PMID: 11097963 Clinical Trial. - Short-acting versus long-acting benzodiazepines: discontinuation effects in panic disorders.
Burrows GD, Norman TR, Judd FK, Marriott PF. Burrows GD, et al. J Psychiatr Res. 1990;24 Suppl 2:65-72. doi: 10.1016/0022-3956(90)90037-q. J Psychiatr Res. 1990. PMID: 1980701 Review.
Cited by
- Assessment of beliefs and attitudes towards benzodiazepines using machine learning based on social media posts: an observational study.
de Anta L, Alvarez-Mon MÁ, Pereira-Sanchez V, Donat-Vargas CC, Lara-Abelenda FJ, Arrieta M, Montero-Torres M, García-Montero C, Fraile-Martínez Ó, Mora F, Ortega MÁ, Alvarez-Mon M, Quintero J. de Anta L, et al. BMC Psychiatry. 2024 Oct 8;24(1):659. doi: 10.1186/s12888-024-06111-5. BMC Psychiatry. 2024. PMID: 39379861 Free PMC article. - Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.
Vinkers CH, Kupka RW, Penninx BW, Ruhé HG, van Gaalen JM, van Haaren PCF, Schellekens AFA, Jauhar S, Ramos-Quiroga JA, Vieta E, Tiihonen J, Veldman SE, Veling W, Vis R, de Wit LE, Luykx JJ. Vinkers CH, et al. Mol Psychiatry. 2024 Aug;29(8):2575-2586. doi: 10.1038/s41380-024-02445-4. Epub 2024 Mar 19. Mol Psychiatry. 2024. PMID: 38503923 Free PMC article. Review. - Trends in the multiple prescriptions of hypnotic drugs in a university outpatient in Japan.
Kato T, Kotorii N, Ozone M, Murotani K, Ohshima H, Mori H, Wasano K, Hiejima H, Habukawa M, Uchimura N. Kato T, et al. Neuropsychopharmacol Rep. 2024 Mar;44(1):80-89. doi: 10.1002/npr2.12386. Epub 2023 Nov 9. Neuropsychopharmacol Rep. 2024. PMID: 37946602 Free PMC article. - The role of pharmacists in deprescribing benzodiazepines: A scoping review.
Ashkanani FZ, Rathbone AP, Lindsey L. Ashkanani FZ, et al. Explor Res Clin Soc Pharm. 2023 Sep 2;12:100328. doi: 10.1016/j.rcsop.2023.100328. eCollection 2023 Dec. Explor Res Clin Soc Pharm. 2023. PMID: 37743854 Free PMC article. Review. - Attitudes and Difficulties Associated with Benzodiazepine Discontinuation.
Takeshima M, Aoki Y, Ie K, Katsumoto E, Tsuru E, Tsuboi T, Inada K, Kise M, Watanabe K, Mishima K, Takaesu Y. Takeshima M, et al. Int J Environ Res Public Health. 2022 Nov 30;19(23):15990. doi: 10.3390/ijerph192315990. Int J Environ Res Public Health. 2022. PMID: 36498061 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical